GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study

OBJECTIVE: To assess the efficacy and safety of lenzilumab in patients with severe coronavirus disease 2019 (COVID-19) pneumonia. METHODS: Hospitalized patients with COVID-19 pneumonia and risk factors for poor outcomes were treated with lenzilumab 600 mg intravenously for three doses through an eme...

Descripción completa

Detalles Bibliográficos
Autores principales: Temesgen, Zelalem, Assi, Mariam, Shweta, F.N.U., Vergidis, Paschalis, Rizza, Stacey A., Bauer, Philippe R., Pickering, Brian W., Razonable, Raymund R., Libertin, Claudia R., Burger, Charles D., Orenstein, Robert, Vargas, Hugo E., Palraj, Raj, Dababneh, Ala S., Chappell, Gabrielle, Chappell, Dale, Ahmed, Omar, Sakemura, Reona, Durrant, Cameron, Kenderian, Saad S., Badley, Andrew D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mayo Foundation for Medical Education and Research 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7470718/
https://www.ncbi.nlm.nih.gov/pubmed/33153629
http://dx.doi.org/10.1016/j.mayocp.2020.08.038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7470718/
https://www.ncbi.nlm.nih.gov/pubmed/33153629
http://dx.doi.org/10.1016/j.mayocp.2020.08.038

Ejemplares similares